Zevra Therapeutics, Inc. (ZVRA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $9.40
- As of
Kresmion compiles this page from ZVRA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ZEVRA THERAPEUTICS, INC. (ZVRA): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-03.
See the full ZVRA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ZVRA on one page. Preview it with sample data, then open it live with a free account.
Preview the ZVRA dossierActive events for ZVRA
- mediumEarnings above estimates
Q3-2026: Beat consensus by 62.7%, EPS $0.26 vs $0.1598 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +578% to ZVRA (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 78% of ZVRA (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 85% of ZVRA (2026Q2)
- high13F: large increase
D. E. Shaw & Co., Inc. added +54% to ZVRA (2026Q2)
FREE, NO ACCOUNT
Every event on ZVRA, as it fires
You are seeing 5 of 12 events recorded on ZVRA since 2026-05-31.
The five above landed across 2 days. The other 7 were recorded on 4 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, ZVRA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
More data on ZVRA
ZVRA against its peers
ZVRA's operating margin of -59.1% ranks in the 65th percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ZVRA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 106M USD | 7.3M USD | 72 | 15 |
| Gross margin | n/a | 69.9% | n/a | 5 |
| Operating margin | -59.1% | -212.8% | 65 | 12 |
| Net margin | 78.2% | -197.6% | 96 | 12 |
| Return on equity | 53.8% | -53.8% | 98 | 21 |
| P / E | 6.9x | n/a | n/a | 2 |
| 1 year | -4.4% | 5.5% | 43 | 21 |
Peers (22): VALN, MYGN, CAPR, EPRX, CBIO, SANA, ENTX, FTH, OBIO, SRZN, RGNX, NGNE, MNPR, GERN, CLYM, OVID, DMAC, STTK, CGEM, GYRE, ABUS, MDXG. Left out: SLBT (no annual filing), IAM (no annual filing), ETRA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ZVRA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ZVRA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ZVRA in the last 180 days.
Upstream: SEC EDGAR filings for ZVRA
Kresmion, "ZEVRA THERAPEUTICS, INC. (ZVRA) institutional holdings and SEC filings", data as of 2026-11-12, https://kresmion.com/research/ZVRA. Upstream data: SEC EDGAR filings for ZVRA.
Link to this data (HTML):
<a href="https://kresmion.com/research/ZVRA">ZEVRA THERAPEUTICS, INC. (ZVRA) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ZVRA on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ZVRA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.